Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$0.32 - $0.67 $164,253 - $343,905
-513,292 Closed
0 $0
Q1 2022

May 05, 2022

BUY
$0.72 - $2.93 $19,491 - $79,320
27,072 Added 5.57%
513,292 $368,000
Q4 2021

Feb 14, 2022

SELL
$2.26 - $3.34 $180,361 - $266,552
-79,806 Reduced 14.1%
486,220 $1.1 Million
Q3 2021

Nov 09, 2021

BUY
$2.35 - $3.88 $30,667 - $50,634
13,050 Added 2.36%
566,026 $1.63 Million
Q2 2021

Jul 29, 2021

SELL
$2.83 - $4.2 $70,738 - $104,983
-24,996 Reduced 4.32%
552,976 $2.1 Million
Q1 2021

May 14, 2021

SELL
$2.92 - $5.06 $2.83 Million - $4.9 Million
-968,197 Reduced 62.62%
577,972 $1.96 Million
Q4 2020

Feb 16, 2021

SELL
$2.22 - $3.78 $73,060 - $124,399
-32,910 Reduced 2.08%
1,546,169 $4.33 Million
Q3 2020

Nov 16, 2020

BUY
$2.39 - $13.08 $492,796 - $2.7 Million
206,191 Added 15.02%
1,579,079 $3.96 Million
Q2 2020

Aug 14, 2020

SELL
$6.67 - $13.58 $228,620 - $465,468
-34,276 Reduced 2.44%
1,372,888 $18.6 Million
Q1 2020

May 15, 2020

BUY
$4.1 - $10.24 $35,026 - $87,480
8,543 Added 0.61%
1,407,164 $10.7 Million
Q4 2019

Jan 29, 2020

SELL
$3.16 - $6.73 $270,230 - $575,522
-85,516 Reduced 5.76%
1,398,621 $8.84 Million
Q3 2019

Oct 30, 2019

SELL
$3.55 - $5.4 $35,262 - $53,638
-9,933 Reduced 0.66%
1,484,137 $5.82 Million
Q2 2019

Aug 01, 2019

SELL
$4.1 - $8.05 $211,609 - $415,476
-51,612 Reduced 3.34%
1,494,070 $7.23 Million
Q1 2019

May 01, 2019

BUY
$5.41 - $8.73 $1.75 Million - $2.83 Million
324,184 Added 26.54%
1,545,682 $12.7 Million
Q4 2018

Feb 14, 2019

BUY
$5.39 - $9.15 $6.37 Million - $10.8 Million
1,181,278 Added 2937.04%
1,221,498 $6.76 Million
Q3 2018

Oct 25, 2018

BUY
$7.44 - $10.65 $299,236 - $428,343
40,220 New
40,220 $355,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $336M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.